<?xml version="1.0" encoding='utf-8' ?>
<nspnews type="text">
<version>v8.0</version>
<date>2026-06-01 17:11:33</date>
<action>I</action>
<registdate>2026-06-01 17:06:13</registdate>
<modifydate>2026-06-01 17:10:40</modifydate>
<publishdate>2026-06-01 17:11:25</publishdate>
<embargo>N</embargo>
<newsid>815158</newsid>
<orgid>815017</orgid>
<language>CN</language>
<category1>21</category1>
<category2>2102</category2>
<category1_name>의학/건강</category1_name>
<category2_name>제약/바이오</category2_name>
<statusID>1</statusID>
<saleID>N</saleID>
<formatID>1</formatID>
<typeID>7</typeID>
<newsSubject><![CDATA[三星生物制剂阿柏西普生物类似药“Opuviz”启动欧洲直营供应]]></newsSubject>
<newsSummary><![CDATA[]]></newsSummary>
<newsTag><![CDATA[삼성바이오에피스,오퓨비즈(Opuviz),아일리아 바이오시밀러,안과질환 치료제]]></newsTag>
<newsLinks><![CDATA[]]></newsLinks>
<news_prolog><![CDATA[(Seoul=NSP NEWS) =]]></news_prolog>
<news1><![CDATA[三星生物制剂近日开始在欧洲通过直营渠道供应眼科疾病治疗药物“Opuviz”低浓度剂型（40mg/ml）。

此次上市的Opuviz是美国再生元公司重磅药物“Eylea（阿柏西普）”的生物类似药，瞄准全球规模约12万亿韩元的相关市场。随着该产品正式供应，三星生物制剂在欧洲直营销售的眼科疾病生物类似药增至两款。此前，公司已于今年1月推出Lucentis（雷珠单抗）生物类似药“Byooviz”。

至此，公司在欧洲直营销售的生物类似药产品总数增至五款。继2023年推出罕见病治疗药物Soliris生物类似药“Epysqli”后，三星生物制剂持续扩大欧洲市场布局。公司表示，此次Opuviz上市将进一步丰富患者治疗选择，并有助于提升其在欧洲生物类似药市场的竞争力。]]></news1>
<news2_title><![CDATA[]]></news2_title>
<news2><![CDATA[]]></news2>
<news3><![CDATA[]]></news3>
<news4_title><![CDATA[]]></news4_title>
<news4><![CDATA[]]></news4>
<news5_title><![CDATA[]]></news5_title>
<news5><![CDATA[]]></news5>
<news_epilog_info><![CDATA[]]></news_epilog_info>
<news_epilog_byline><![CDATA[By Jiwon Lee(won2514@nspna.com) and Songyi Jeong(qu225577@nspna.com)]]></news_epilog_byline>
<news_epilog><![CDATA[ⓒNSP News Agency·NSP TV. All rights reserved.]]></news_epilog>
<imageL><![CDATA[https://file.nspna.com/news/2026/06/01/20260601170747_815158_0.jpg]]></imageL>
<imageP><![CDATA[https://file.nspna.com/news/2026/06/01/photo_20260601170747_815158_0.jpg]]></imageP>
<image1><![CDATA[https://file.nspna.com/news/2026/06/01/20260601170747_815158_1.jpg]]></image1>
<image2><![CDATA[]]></image2>
<image3><![CDATA[]]></image3>
<image4><![CDATA[]]></image4>
<image5><![CDATA[]]></image5>
<image1_place><![CDATA[c]]></image1_place>
<image2_place><![CDATA[c]]></image2_place>
<image3_place><![CDATA[c]]></image3_place>
<image4_place><![CDATA[c]]></image4_place>
<image5_place><![CDATA[c]]></image5_place>
<image1_text><![CDATA[]]></image1_text>
<image2_text><![CDATA[]]></image2_text>
<image3_text><![CDATA[]]></image3_text>
<image4_text><![CDATA[]]></image4_text>
<image5_text><![CDATA[]]></image5_text>
<image1_source><![CDATA[]]></image1_source>
<image2_source><![CDATA[]]></image2_source>
<image3_source><![CDATA[]]></image3_source>
<image4_source><![CDATA[]]></image4_source>
<image5_source><![CDATA[]]></image5_source>
<vodSite><![CDATA[]]></vodSite>
<vodID><![CDATA[]]></vodID>
<vodTitle><![CDATA[]]></vodTitle>
<vodWidth><![CDATA[]]></vodWidth>
<vodHeight><![CDATA[]]></vodHeight>
<advertorial><![CDATA[]]></advertorial>
<location><![CDATA[Seoul]]></location>
<teamID>110</teamID>
<teamName><![CDATA[국제부]]></teamName>
<writerID>won2514</writerID>
<writerName><![CDATA[Jiwon Lee]]></writerName>
<writerTitle><![CDATA[Reporter]]></writerTitle>
<writerEmail><![CDATA[won2514@nspna.com]]></writerEmail>
<writerID2>qu225577</writerID2>
<writerName2><![CDATA[Songyi Jeong]]></writerName2>
<writerTitle2><![CDATA[Reporter]]></writerTitle2>
<writerEmail2><![CDATA[qu225577@nspna.com]]></writerEmail2>
<writerID3></writerID3>
<writerName3><![CDATA[]]></writerName3>
<writerTitle3><![CDATA[]]></writerTitle3>
<writerEmail3><![CDATA[]]></writerEmail3>
</nspnews>
